ReviewInternational journal of environmental research and public health2023
Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours.
Review in International journal of environmental research and public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- The Role of CA-125 in the Management of Ovarian Cancer: A Systematic Review.Cancer reports (Hoboken, N.J.) · 2025Pooled it
- Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study.Therapeutics and clinical risk management · 2025Trial
- Treatment patterns and survival outcomes according to histologic subtype in malignant ovarian germ cell tumors: a nationwide real-world cohort study.Journal of gynecologic oncology · 2026Article
- Clinical Features of Malignant Ovarian Germ Cell Tumors According to Demographic and Pathologic Characteristics.Health science reports · 2026Article
- Article
- Outcomes of Pediatric and Adolescent Girls with Malignant Ovarian Germ Cell Tumors after Chemotherapy and Surgery: A Single Institutional Experience.Journal of cancer & allied specialties · 2026Article
- Prevalence and Management of Nonepithelial Ovarian Cancer in a Sub-Saharan African Setting.Obstetrics and gynecology international · 2026Article
- Granulocyte colony-stimulating factor-induced hypersensitivity reaction with leukocytosis in a pediatric germ cell tumor patient: a case report.Frontiers in pediatrics · 2026Article
- Epidemiology and treatment of malignant ovarian germ cell and sex cord stromal tumors in germany: a population-based cancer registry study from 2016 - 2021.Scientific reports · 2025Article
- Ovarian Tumor Biomarkers: Correlation Between Tumor Type and Marker Expression, and Their Role in Guiding Therapeutic Strategies.International journal of molecular sciences · 2025Review
- MicroRNA Signatures in Serous Ovarian Cancer: A Comparison of Prognostic Marker Targets in African Americans and Caucasians.Diseases (Basel, Switzerland) · 2025Article
- Ovarian Collision Tumor in a Pediatric Patient: A Mature Teratoma Associated with a Combined Tumor Containing a Mucinous Cystadenocarcinoma Component.Journal of clinical medicine · 2025Article
- Voluminous bilateral malignant ovarian germ cell tumors with carcinomatosis in a child.Radiology case reports · 2025Article
- Redefining Risk, Biomarkers, and Precision Therapy for Hereditary Ovarian Cancer: A Review.ACS omega · 2025Review
- Article
- Integrative approach for enhanced ovarian cancer diagnosis: cytology and biomarkers.Discover oncology · 2025Article
- Dual-responsive nanoscale ultrasound contrast agent as an oxidative stress amplifier for enhanced DNA damage in BRCA-proficient ovarian cancer.Materials today. Bio · 2025Article
- Malignant germ cells tumor of the ovary.Journal of gynecologic oncology · 2025Review
- Thymoquinone Enhances Doxorubicin Efficacy via RAS/RAF Pathway Modulation in Ovarian Adenocarcinoma.Pharmaceutics · 2025Article
- The impact of the COVID-19 pandemic on the diagnosis, treatment, and prognosis of ovarian cancer in the United States: a retrospective cohort study based on the SEER database.Discover oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonepithelial ovarian cancers (NEOC) are a group of rare malignancies, including germ cell tumours (GCT) and sex cord-stromal tumours (SCST), along with small-cell carcinomas and sarcomas. GCTs represent 2-5% of ovarian cancers, with a yearly incidence of 4:100,000, and they usually affect young women and adolescents. Precursory germ cells of the ovary form the basis of GCT. They are histologically classified into primitive GCT, teratomas, and monodermal and somatic-type tumours associated with dermoid cysts. A primitive GCT can be either a yolk sac tumour (YST), dysgerminoma, or mixed germ cell neoplasm. Teratomas are either mature (benign) or immature (malignant). Given that malignant GCTs occur rarely compared to epithelial ovarian tumours (EOC), greater focus is required in their diagnosis and treatment. In this article, we review the epidemiology, clinical manifestations, diagnosis, and molecular biology, along with the management and therapeutic challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.